Upgrade to SI Premium - Free Trial

Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell

November 8, 2016 11:00 AM
Leerink affirms its Outperform rating and $22 price target on Depomed (Nasdaq: DEPO) following Q3 results and update on Monday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles